Angiotensin II and aldosterone-induced neuronal damage in neurons through an astrocyte-dependent mechanism

Hypertension Research

Volumn 34, Issue 6, 2011, Pages 773-778

  Min, Li Juan ^a   Mogi, Masaki ^a   Iwanami, Jun ^a   Sakata, Akiko ^a   Jing, Fei ^a   Tsukuda, Kana ^a   Ohshima, Kousei ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

aldosterone; angiotensin II; astrocyte; central nervous system disorder; neuronal damage

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; EPLERENONE; VALSARTAN;

ANIMAL CELL; ARTICLE; ASTROCYTE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DNA DAMAGE; EMBRYO; FLOW CYTOMETRY; MOUSE; NERVE CELL LESION; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPINAL GANGLION;

ALDOSTERONE; ANGIOTENSIN II; ANIMALS; ASTROCYTES; CELLS, CULTURED; DNA DAMAGE; GANGLIA, SPINAL; MICE; MICE, INBRED C57BL; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; TETRAZOLES; VALINE;

EID: 79958122331     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.38     Document Type: Article

References (35)

1. Kazantsev AG. Cellular pathways leading to neuronal dysfunction and degeneration. Drug News Perspect 2007; 20: 501-509. (Pubitemid 351182793)
2. Seifert G, Schilling K, Steinhauser C. Astrocyte dysfunction in neurological disorders: molecular perspective. Nat Rev Neurosci 2006; 7: 194-206. (Pubitemid 43292465)
3. Fonseca MI, Kawas CH, Troncoso JC, Tenner AJ. Neuronal localization of C1q in preclinical Alzheimer's disease. Neurobiol Dis 2004; 15: 40-46. (Pubitemid 38134379)
4. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 2007; 10: 615-622. (Pubitemid 46652435)
5. Barber SC, Mead RJ, Shaw PJ. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta 2006; 1762: 1051-1067. (Pubitemid 44750575)
6. Wilkinson BL, Landreth GE. The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J Neuroinflam 2006; 3: 30.
7. Unger T, Jakobsen A, Heroys J, Ralph A, Rees T, Shaw M. Targeting cardiovascular protection: the concept of dual renin-angiotensin system control. Medscape J Med 2008; 10(Suppl): S4.
8. Brenner D, Labreuche J, Pico F, Scheltens P, Poirier O, Cambien F, Amarenco P, GENIC Investigators. The renin-angiotensin-aldosterone system in cerebral small vessel disease. J Neurol 2008; 255: 993-1000.
9. Mollsten A, Stegmayr B, Wiklund PG. Genetic polymorphisms in the renin-angiotensin system confer increased risk of stroke independently of blood pressure: a nested casecontrol study. J Hypertens 2008; 26: 1367-1372.
10. Kawajiri M, Mogi M, Higaki N, Tateishi T, Ohyagi Y, Horiuchi M, Miki T, Kira JI. Reduced angiotensin II levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2009; 119: 341-344.
11. Iwasaki Y, Ichikawa Y, Igarashi O, Kinoshita M, Ikeda K. Trophic effect of olmesartan, a novel AT1R antagonist, on spinal motor neurons in vitro and in vivo. Neurol Res 2002; 24: 468-472. (Pubitemid 34742680)
12. Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003; 24: 261-271. (Pubitemid 36733542)
13. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond) 2007; 113: 267-278. (Pubitemid 47372685)
14. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 2005; 97: 434-442. (Pubitemid 41298173)
15. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002; 40: 504-510.
16. Ahmad Z, Milligan CJ, Paton JF, Deuchars J. Angiotensin type 1 receptor immunoreactivity in the thoracic spinal cord. Brain Res 2003; 985: 21-31. (Pubitemid 37272049)
17. Oyamada N, Sone M, Miyashita K, Park K, Taura D, Inuzuka M, Sonoyama T, Tsujimoto H, Fukunaga Y, Tamura N, Itoh H, Nakao K. The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia. Endocrinology 2008; 149: 3764-3777.
18. Clark MA, Guillaume G, Pierre-Louis HC. Angiotensin II induces proliferation of cultured rat astrocytes through c-Jun N-terminal kinase. Brain Res Bull 2008; 75: 101-106. (Pubitemid 350297646)
19. Chou YC, Luttge WG, Sumners C. Expression of mineralocorticoid type I and glucocorticoid type II receptors in astrocyte glia as a function of time in culture. Brain Res Dev Brain Res 1991; 61: 55-61.
20. Zimmerman MC, Sharma RV, Davisson RL. Superoxide mediates angiotensin II-induced influx of extracellular calcium in neural cells. Hypertension 2005; 45: 717-723. (Pubitemid 40418371)
21. Zhang ZH, Yu Y, Kang YM, Wei SG, Felder RB. Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. Am J Physiol Heart Circ Physiol 2008; 294: H1067-H1074. (Pubitemid 351253321)
22. Gushchina S, Leinster V, Wu D, Jasim A, Demestre M, Lopez De Heredia L, Michael GJ, Barker PA, Richardson PM, Magoulas C. Observation on the function of nuclear factor kappa B (NF-kappaB) in the survival of adult primary sensory neurons after nerve injury. Mol Cell Neurosci 2009; 40: 207-216.
23. Sporns O, Edelman GM, Crossin KL. The neural cell adhesion molecule (N-CAM) inhibits proliferation in primary cultures of rat astrocytes. Proc Natl Acad Sci USA 1995; 92: 542-546.
24. Martinet W, Knaapen MW, De Meyer GR, Herman AG, Kockx MM. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation 2002; 106: 927-932. (Pubitemid 34925325)
25. Emerit J, Edeas M, Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed Pharmacother 2004; 58: 39-46. (Pubitemid 38117047)
26. Ito T, Yamakawa H, Bregonzio C, Terron JA, Falcon-Neri A, Saavedra JM. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 2002; 33: 2297-2303. (Pubitemid 35014646)
27. Tsukuda K, Mogi M, Li JM, Iwanami J, Min LJ, Sakata A, Fujita T, Iwai M, Horiuchi M. Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan. Hypertension 2007; 50: 1099-1105. (Pubitemid 350172932)
28. Iwanami J, Mogi M, Okamoto S, Gao XY, Li JM, Min LJ, Ide A, Tsukuda K, Iwai M, Horiuchi M. Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model. Eur J Pharmacol 2007; 566: 153-159. (Pubitemid 46782806)
29. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, Humala N, Seror I, Bartholomew S, Rosendorff C, Pasinetti GM. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117: 3393-3402. (Pubitemid 350096995)
30. Blackburn D, Sargsyan S, Monk PN, Shaw PJ. Astrocyte function and role in motor neuron disease: a future therapeutic target? Glia 2009; 57: 1251-1264.
31. Ricart K, J Pearson Jr R, Viera L, Cassina P, Kamaid A, Carroll SL, Estevez AG. Interactions between beta-neuregulin and neurotrophins in motor neuron apoptosis. J Neurochem 2006; 97: 222-233.
32. Min LJ, Mogi M, Iwanami J, Li JM, Sakata A, Fujita T, Tsukuda K, Iwai M, Horiuchi M. Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence. Cardiovasc Res 2007; 76: 506-516. (Pubitemid 350007454)
33. Danielyan L, Lourhmati A, Verleysdonk S, Kabisch D, Proksch B, Thiess U, Umbreen S, Schmidt B, Gleiter CH. Angiotensin receptor type 1 blockade in astroglia decreases hypoxia-induced cell damage and TNF alpha release. Neurochem Res 2007; 32: 1489-1498. (Pubitemid 47094411)
34. Tsukuda K, Mogi M, Iwanami J, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M. Cognitive deficit in amyloid-b-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferators- activated receptor-g activation. Hypertension 2009; 54: 782-787.
35. Iwanami J, Mogi M, Tsukuda K, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferators-activated receptor-g activation in diabetic mice. J Hypertens 2010; 28: 1730-1737.